

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/028541 A3

- (51) International Patent Classification⁷: **A61K 31/4985**, 31/5517, A61P 35/00
- (74) Agents: **HALL, Robert, L.** et al.; Harrison Goddard Foote, Fountain Precinct, Balm Green, Sheffield S1 2JA (GB).
- (21) International Application Number: PCT/IB2003/004922
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 29 September 2003 (29.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (30) Priority Data: 60/414,103 27 September 2002 (27.09.2002) US
- (71) Applicants (*for all designated States except US*): **SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S.** [FR/FR]; 51-53 rue du Docteur Blanche, F-75016 Paris (FR). **CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE** [FR/FR]; 3, rue Michel-Ange, F-75794 Paris Cedex 16 (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **PREVOST, Gregoire** [FR/FR]; 5, avenue du Canada, F-91966 Les Ulis (FR). **BUSSON, Pierre** [FR/FR]; 39, rue Camille Desmoulins, F-94805 Ville Juif (FR). **VICAT, Jean-Michel** [FR/FR]; 39, rue Camille Desmoulins, F-94805 Ville Juif (FR).
- Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- (88) Date of publication of the international search report: 1 July 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMPOSITION FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA AND USE THEREOF

(57) Abstract: Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor and one or more of an anthracycline.

WO 2004/028541 A3

Best Available Copy

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 03/04922

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/4985 A61K31/5517 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/64197 A (JANSSEN PHARMACEUTICA NV ;RYBAK MARY ELLEN MARGARET (US)) 7 September 2001 (2001-09-07) page 18, line 34 -page 19, line 20; claims 1,9-14; figure IX	1-40
P,X	VICAT, J.-M- ET AL.: "Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treated with doxorubicin combined with a farnesyl-transferase inhibitor" BIOCHEMICAL PHARMACOLOGY, vol. 65, no. 3, 2003, pages 423-433, XP002273795 abstract; figure 2	1-40

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *A* document member of the same patent family

Date of the actual completion of the international search

5 April 2004

Date of mailing of the international search report

21/04/2004

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beyss, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 03/04922

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/39130 A (SOD CONSEILS RECH APPLIC ;GORDON THOMAS B (US); MORGAN BARRY A (US) 6 July 2000 (2000-07-06) claims 1,16 -----	1-40
X	WO 97/30053 A (BIOMEASURE INC) 21 August 1997 (1997-08-21) claim 1 -----	1-40

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 03/04922

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 26-33 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 03/04922

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0164197	A	07-09-2001	AU 4416701 A	12-09-2001
			CA 2397253 A1	07-09-2001
			WO 0164197 A2	07-09-2001
			EP 1267872 A2	02-01-2003
			JP 2003525237 T	26-08-2003
WO 0039130	A	06-07-2000	AT 261447 T	15-03-2004
			AU 2717100 A	31-07-2000
			CA 2356756 A1	06-07-2000
			CZ 20012358 A3	16-01-2002
			EP 1382607 A2	21-01-2004
			EP 1140942 A2	10-10-2001
			HU 0104708 A2	29-04-2002
			NO 20013281 A	29-08-2001
			WO 0039130 A2	06-07-2000
WO 9730053	A	21-08-1997	US 2002013319 A1	31-01-2002
			AU 716636 B2	02-03-2000
			AU 1964597 A	02-09-1997
			CA 2245823 A1	21-08-1997
			CN 1216545 A	12-05-1999
			EP 0904274 A1	31-03-1999
			JP 2001500838 T	23-01-2001
			PL 328513 A1	01-02-1999
			TW 432066 B	01-05-2001
			WO 9730053 A1	21-08-1997
			ZA 9701254 A	14-07-1998
			RU 2201931 C2	10-04-2003
			US 2003119864 A1	26-06-2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/028541 A2

(51) International Patent Classification⁷: **A61K 31/4985**,
31/5517, A61P 35/00

Jean-Michel [FR/FR]; 39, rue Camille Desmoulins,
F-94805 Ville Juif (FR).

(21) International Application Number:
PCT/IB2003/004922

(74) Agents: **HALL, Robert, L.** et al.; Harrison Goddard
Foote, Fountain Precinct, Balm Green, Sheffield S1 2JA
(GB).

(22) International Filing Date:
29 September 2003 (29.09.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/414,103 27 September 2002 (27.09.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): SOCI-
ETE DE CONSEILS DE RECHERCHES ET D'AP-
PLICATIONS SCIENTIFIQUES, S.A.S. [FR/FR];
51-53 rue du Docteur Blanche, F-75016 Paris (FR). CEN-
TRE NATIONAL DE RECHERCHE SCIENTIFIQUE
[FR/FR]; 3, rue Michel-Ange, F-75794 Paris Cedex 16
(FR).

Published:

— *without international search report and to be republished
upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PREVOST,**
Gregoire [FR/FR]; 5, avenue du Canada, F-91966
Les Ulis (FR). **BUSSON, Pierre** [FR/FR]; 39, rue
Camille Desmoulins, F-94805 Ville Juif (FR). **VICAT,**

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 2004/028541 A2

(54) Title: COMPOSITION FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA AND METHOD OF USE THEREOF

(57) Abstract: Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor and one or more of an anthracycline.

5 COMPOSITION FOR THE TREATMENT OF NASOPHARYNGEAL
CARCINOMA AND METHOD OF USE THEREOF

BACKGROUND OF THE INVENTION

Nasopharyngeal carcinoma (NPC), a human squamous cell cancer, arises in the
10 surface epithelium of the posterior nasopharynx. (Liao, W.C., et al., Int. J of Oncology
17: 323-328 (2000)). Undifferentiated NPC's have several remarkable features which
make them unique among human epithelial malignancies. (Ablashi, D., et al., Epstein-
Barr virus and Kaposi's sarcoma Herpesvirus/Human Herpesvirus 8 IARC
monographs on the evaluation of carcinogenic risks to humans. IARC, Lyon, France,
15 n°70:97.) They are rare in most countries but they occur with a high incidence in some
selected areas, especially Southeast Asia and North Africa.

NPC is consistently associated with the Epstein-Barr virus (EBV) regardless of
patient geographic origin. On tissue sections, NPC appears to be heavily infiltrated by
non-malignant lymphocytes mostly of the T-lineage. The full length genome of EBV
20 is contained in all malignant epithelial cells and consistently encodes several viral
products which are likely to contribute to the malignant phenotype. However, there is
no production of viral particles in tumor cells; in other words, NPC cells are mainly in
a state of "latent" EBV-infection. Some of the latent viral products are the EBNA1
protein and two species of small untranslated RNA's, called EBER 1 and 2. Another
25 EBV-protein called Latent Membrane Protein 1 (LMP1) is produced in about 50% of
NPC's. Other viral RNA messengers and their corresponding proteins are under
investigation. (Fries, K. L., et al., Identification of a novel protein encoded by the
BamHI A region of the Epstein-Barr virus. J Virol, 71 : 2765-2771, 1997; Kienzle, N.,
et al., Epstein-Barr virus-encoded RK-BARF0 protein expression. J Virol, 73 : 8902-
30 8906, 1999; Decaussin, G., et al., Expression of BARF1 gene encoded by Epstein-
Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res, 60 : 5584-5588, 2000.)

NPC oncogenesis is also promoted by cellular gene alterations. Inactivation of
the p16/INK4 gene by point mutations or hypermethylation is the most consistent of
these alterations. (Lo, K. W., et al., Hypermethylation of the p16 gene in
35 nasopharyngeal carcinoma. Cancer Res, 56 : 2721-2725, 1996.) Small homozygous

deletions or losses of heterozygosity frequently occur in chromosome 3p suggesting that this region contains a tumor-suppressor gene which is critical for NPC-oncogenesis. (Lo, K. W., et al., High resolution allelotype of microdissected primary nasopharyngeal carcinoma. *Cancer Res*, 60 : 3348-3353, 2000.) In contrast with data
5 recorded in most other human epithelial malignancies, p53 is rarely mutated in NPC. (Effert, P., et al., Alterations of the p53 gene in nasopharyngeal carcinoma. *J Virol*, 66 : 3768-3775, 1992.) A functional inactivation of p53 has been suspected by some authors but the mechanism of this potential inactivation remains to be elucidated. (Fries, K. L. et al., Epstein-Barr virus latent membrane protein 1 blocks p53-mediated
10 apoptosis through the induction of the A20 gene. *J Virol*, 70 : 8653-8659, 1996.)

Malignant NPC cells have a short doubling time and a high metastatic potential. Nevertheless, they are prone to enter apoptosis both in situ and in vitro. In the majority of cases, the apoptotic index is high on tissue sections of NPC's. (Harn, H. J., et al., Apoptosis in nasopharyngeal carcinoma as related to histopathological
15 characteristics and clinical stage. *Histopathology*, 33 : 117-122, 1998.) In addition, it has been shown that NPC cells strongly express CD95 and are highly sensitive to CD95-mediated apoptosis in vitro. (Sbihi-Lammali, F., et al., Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. *Cancer Res*, 59 : 924-930, 1999.)

20 Vulnerability to apoptosis may in part explain why NPC's have a higher sensitivity to radiotherapy and chemotherapy than most other head and neck carcinomas. Radiotherapy is the basic therapeutic arm for treatment of the primary tumors, but in a growing number of cases it is combined with induction, concomitant or adjuvant chemotherapy. (Ali, H. et al., Chemotherapy in advanced nasopharyngeal
25 cancer. *Oncology (Huntingt)*, 14:1223-1230, 2000.) Short term results of induction chemotherapy are often remarkable. The rate of complete remissions is routinely of 10 to 25% following two to three courses of induction chemotherapy. (Benasso, M., et al., Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma. *Br J Cancer*, 83 : 1437-1442, 2000; Chua,
30 D. T., et al., Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospital

experience. *Int J Radiat Oncol Biol Phys*, 49 : 1219-1228, 2001.) In some studies, the rate of complete lymph node regressions can reach 50%. (Frikha, M., et al., Evaluation of tumoral and lymph node response to neoadjuvant chemotherapy in undifferentiated nasopharyngeal carcinoma, *Bull Cancer*, 84 : 273-276, 1997.)
5 However, these good responses are unpredictable and often of short duration. In addition, in only a few studies were good short term responses to induction chemotherapy associated with some improvement in long term survival. (Benasso, M., et al., Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma. *Br J Cancer*, 83 : 1437-1442, 2000.)

10 So far, despite its major role in the treatment of NPC, the effects of chemotherapy on EBV-positive NPC cells have been poorly investigated. One major reason is the extreme difficulty of growing NPC cells in vitro. For several decades the only source of experimental NPC materials were tumor lines propagated into nude mice as xenografts and only a small fraction of clinical NPC specimens could be
15 successfully grafted. (Busson, P., et al., Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. *Int J Cancer*, 42:599-606, 88.) More recently, there were reports of NPC cell lines propagated in vitro but many of these lines do not contain EBV, thus may not be truly representative of in vivo NPC cells. (Lin, C. T., et al., Association of Epstein-Barr virus, human papilloma virus, and
20 cytomegalovirus with nine nasopharyngeal carcinoma cell lines. *Lab Invest*, 71:731-736., 1994.) Significant progress was made by derivation from a Chinese NPC xenograft called Xeno-666, of a subclone called C666-1 which can be permanently grown in vitro and which retains the EBV genome. (Cheung, S. T., et al., Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr
25 virus. *Int J Cancer*, 83:121-126, 1999.) We have also made progress in improving short term in vitro cultures of cells derived from other NPC xenografts, especially the C15 North African NPC xenograft.

The biological mechanisms which underlie the cytotoxic effects of anti-neoplastic drugs in NPC cells has yet to be fully elucidated. There are few reports in
30 the literature on this topic and these have been focused mainly on the effects of cisplatin and taxol. Cisplatin was shown to induce growth arrest in the CNE1 NPC

cell line at concentrations of about 1 μ M. This growth arrest was accompanied by increased expression of senescence-associated β -galactosidase. (Wang, X., et al., Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. *Cancer Res*, 58 : 5019-5022, 1998; Wang, X., et al., Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells. *Anticancer Res*, 21 : 403-408, 2001.) Taxol was shown to induce growth arrest and/or apoptosis in TWO1 and TW039 NPC cell lines. (Lou, P.J. et al., Taxol reduces cytosolic E-cadherin and beta-catenin levels in nasopharyngeal carcinoma cell line TW-039: cross-talk between the microtubule- and actin-based cytoskeletons. *J Cell Biochem*, 79 : 542-556, 2000; Huang, T. S., et al., Activation of MAD 2 checkpoint and persistence of cyclin B1/CDC 2 activity associate with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. *Apoptosis*, 5:235-241, 2000.) Significantly, however, the foregoing studies were performed on EBV-negative cell lines which either had been derived from rare forms of EBV-negative differentiated NPC's (CNE1, TW039), or had lost the EBV-genome after a few passages *in vitro* (TWO1). (Lin, C. T., et al., Association of Epstein-Barr virus, human papilloma virus, and cytomegalovirus with nine nasopharyngeal carcinoma cell lines. *Lab Invest*, 71:731-736., 1994.) Thus the target cell lines of the foregoing studies cannot be regarded as truly representative of undifferentiated EBV-positive NPC's.

Testing anti-neoplastic drugs on genuine EBV-positive NPC cells *in vitro* recently was made possible by technical developments in the handling of the C666-1 and C15 NPC tumor lines. As noted above, C666 was derived from the xeno 666 transplanted NPC. C666 was subsequently subcloned in order to stabilize its association with the EBV-genome, C666-1 being one of the resulting clones. In contrast, a permanent *in vitro* cell line has yet to be derived from the C15 transplanted NPC. However the selective *in vitro* growth of malignant C15 cells can be and was obtained through the use of a PolyHema matrix. The PolyHema matrix prevented the proliferation of murine fibroblasts and allowed for the proliferation of C15 cells in the form of small floating aggregates.

30

Farnesyl transferase inhibitors (FTIs)

Farnesyl transferase inhibitors (FTIs) are molecularly targeted drugs which have been observed to induce malignant cell apoptosis in some experimental systems. There are some indications that FTIs can increase the benefit of chemotherapy or radiotherapy without a parallel increase in undesirable side-effects. (Moasser, M. M. et al., Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. *Proc Natl Acad Sci USA*, 95:1369-1374, 1998; Sebti, S. M. et al., Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. *Oncogene*, 19: 6584-6593, 2000.) Although FTIs were initially designed to inhibit the farnesylation and membrane anchoring of ras proteins, it is now clear that they interfere with farnesylation of other proteins, as well, especially Rho B, rap 2, and lamin A and B. Cell treatment with FTIs has been observed to result in the accumulation of geranylated Rho B which induces apoptosis of transformed cells. (Prendergast, G. C. et al., Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. *Semin Cancer Biol*, 10 : 443-452., 2000.) In other cellular models FTIs have been shown to inhibit the PI-3 kinase pathway. (Plo, I., et al., The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. *FEBS Lett*, 452 : 150-154., 1999.)

20 Anthracyclins

Anthracyclins such as doxorubicin classically exert their cytotoxic effect by inducing production of reactive oxygen species (ROS). ROS can induce DNA lesions, p53 activation resulting in up-regulation of p21/waf1, GADD 45, CD95 and Bax. (Kostic, C. et al., Isolation and characterization of sixteen novel p53 response genes. *Oncogene*, 19 : 3978-3987., 2000.) ROS also have some impact on membrane lipids and can induce production of lipid second messengers. (Bettaieb, A., et al., Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramide generation and apoptosis. *Mol Pharmacol*, 55: 118-125., 1999.)


30

Presently it is difficult to know where and how the FTT- and doxorubicin-modified pathways intersect in such a way that they induce apoptosis. It has been postulated that caspase 8 is a key-effector of TRAF1-cleavage during CD-95-mediated apoptosis. (Leo, E., et al., TRAF1 is a substrate of caspases activated during tumor
5 necrosis factor receptor- α induced apoptosis. J Biol Chem, 55:8087-8093, 2000.) However, the cleavage of TRAF1 induced by drugs has some distinct features when compared to the cleavage induced by CD95-agonists. Among these features is a sustained high ratio of uncleaved to cleaved forms of TRAF-1 in drug-treated samples, suggesting that an increase in TRAF1 production occurs in drug-treated NPC
10 cells in parallel with the cleavage process. Interestingly, the same high ratio of cleaved to uncleaved molecules was reported by Leo et al. for the HT1080 cell line expressing exogenous TRAF1 and treated by doxorubicin. (Id.)

TRAF1 has a very restricted tissue distribution. As in the case of EBV-transformed B-lymphocytes the strong expression of TRAF1 in NPC is likely to be
15 related to the presence of EBV. (Mosialos, G., et al., The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 80 : 389-399, 1995.) Thus cleavage of TRAF1 would be a useful marker for specifically monitoring chemo-induced apoptosis in NPC cells, for example in biopsy material.

20 In the cell viability assay, below, both C15 and C666-1 were observed to be remarkably sensitive to the cytotoxic effects of doxorubicin at concentrations below 1 μ M. However, neither doxorubicin nor taxol induced apoptosis on its own. Interestingly, doxorubicin was included in the combination of drugs that had achieved a marked – although transient - tumor regression in the patient who was the donor of
25 the C15 tumor line.

Doxorubicin was combined with FTT's in order to achieve chemo-induced apoptosis of NPC cells and to increase cytotoxicity. Compound A is a selective inhibitor of the farnesyl-transferase enzyme having the following structure:




The cytotoxic effect of doxorubicin against both C15 and C666-1 cells was dramatically enhanced when it was used in combination with Compound A. The cytotoxic effect of against C15 cells was associated with massive apoptosis, associated with early cleavage of TRAF1, 48 h after starting cell exposure to the combination. The cytotoxic effect against C666-1 cells was associated with growth arrest and non-characterized cell death, apoptotic events not being observed at the tested concentrations.

It is noteworthy that in the same assay, below, both C15 cells and even more noticeably C666-1 cells were less sensitive to cis-platin than to doxorubicin. This result is consistent with a previous report of poor sensitivity of C666-1 cells to cis-platinum in a short term cytotoxicity assay. (Weinrib, L., et al., Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. Cancer Gene Ther, 8: 352-360., 2001.) These results are surprising since cis-platinum is currently regarded as the most effective agent in the chemotherapy of NPC's. (Ali, H. et al., Chemotherapy in advanced nasopharyngeal cancer. Oncology (Huntingt), 14 : 1223-1230, 2000.)

SUMMARY OF THE INVENTION

In a first aspect the present invention features a pharmaceutical composition comprising a farnesyl transferase inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said farnesyl transferase inhibitor or of said farnesyl transferase inhibitor prodrug, and an anthracycline, a prodrug thereof or a pharmaceutically acceptable salt of said anthracycline or of said anthracycline prodrug.

According to a first preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound which is disclosed in International Patent Application Publication No. WO 00/39130; i.e., a compounds according to formula I:



wherein

n_1 is 0 or 1;

X is, independently for each occurrence, $(\text{CHR}^{11})_{n3}(\text{CH}_2)_{n4}\text{Z}(\text{CH}_2)_{n5}$;


Z is O, N(R^{12}), S, or a bond;

n_3 is, independently for each occurrence, 0 or 1;

n_4 and n_5 each is, independently for each occurrence, 0, 1, 2, or 3;

Y is, independently for each occurrence, CO, CH_2 , CS, or a bond;

R^1 is



R^2 , R^{11} , and R^{12} each is, independently for each occurrence, H or an

optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl and aryl, wherein said optionally substituted moiety is optionally substituted with one or more of R^8 or R^{30} ;

R^3 is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more R^{30} ;

R^4 and R^5 each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, aryl, and heterocyclyl, wherein said optionally substituted moiety is optionally substituted with one or more R^{30} , wherein each said substituent is independently selected, or R^4 and R^5 can be taken together with the carbons to which they are attached to form aryl;


R^6 is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, -N(R^8R^9), -COOH, -CON(R^8R^9), and halo,

where R^8 and R^9 each is, independently for each occurrence, H, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, aryl, or aryl(C₁₋₆)alkyl;

R^7 is, independently for each occurrence, H, =O, =S, or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, -N(R^8R^9), -COOH, -CON(R^8R^9), and halo;

R^{10} is C; or when $n1 = 0$, R^6 and R^7 can be taken together with the carbon atoms to which they are attached to form aryl or cyclohexyl;

- R^{21} is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl and aryl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of R^8 and R^{30} ;
- 5 R^{22} is H, (C₁₋₆)alkylthio, (C₃₋₆)cycloalkylthio, R^8-CO- , or a substituent according to



the formula


- R^{24} and R^{25} each is, independently for each occurrence, H, (C₁₋₆)alkyl, or aryl(C₁₋₆)alkyl;
- R^{30} is, independently for each occurrence, (C₁₋₆)alkyl, $-O-R^8$, $-S(O)_{n6}R^8$, $-S(O)_{n7}N(R^8R^9)$, $-N(R^8R^9)$, $-CN$, $-NO_2$, $-CO_2R^8$, $-CON(R^8R^9)$, $-NCO-R^8$, or halogen;
- 10 $n6$ and $n7$ each is, independently for each occurrence, 0, 1, or 2;
- wherein said heterocyclyl is azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnoliny, dihydrobenzofuryl,
- 15 dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazoliny, imidazolyl, indoliny, indolyl; isochromanyl, isoindoliny, isoquinoliny, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholiny, naphthyridiny, oxadiazolyl, 2-oxoazepiny, 2-oxopiperaziny, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperaziny, pyridyl, pyridyl N-oxide,
- 20 quinoxaliny, tetrahydrofuryl, tetrahydroisoquinoliny, tetrahydro-quinoliny, thiamorpholiny, thiamorpholiny sulfoxide, thiazolyl, thiazoliny, thienofuryl, thienothiényl, or thienyl; and

wherein said aryl is phenyl or naphthyl;


provided that:

25


when $n1 = 1$, R^{10} is C and R^6 is H, then R^{10} and R^7 can be taken together to form



when $n1 = 1$, R^{10} is C, and R^7 is =O, -H, or =S, then R^{10} and R^6 can be taken together



when R^1 is $\text{N}(R^{24}R^{25})$, then $n3$ is 1, $n4$ and $n5$ each is 0, Z is a bond, and R^3 and R^{11}




can be taken together to form

10 wherein $n2$ is 1-6, and X^4 and X^5 each is, independently, H, (C_{1-6}) alkyl, or aryl, or X^4 and X^5 can be taken together to form (C_{3-6}) cycloalkyl;

or a pharmaceutically acceptable salt thereof.

According to a second preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I,


15 wherein:



X is $\text{CH}(R^{11})_{n3}(\text{CH}_2)_{n4}$ or Z, wherein when X is Z, Z is O, S, or $\text{N}(R^{12})$;

or a pharmaceutically acceptable salt thereof.

According to a first more preferred embodiment of said second preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein:




R¹ is ;

5 X is CH(R¹¹)_{n3}(CH₂)_{n4}; and

n₁ is 0;

or a pharmaceutically acceptable salt thereof.

According to a second more preferred embodiment of said second preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein:



R¹ is R²²-S ;

n₃, n₄, and n₅ each is 0;


Z is a bond;

Y is, independently for each occurrence, CO or CS; and

15 n₁ is 0;

or a pharmaceutically acceptable salt thereof.


According to a third more preferred embodiment of said second preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein:



20 R¹ is ;

R⁶ is H;

n₁ is 1;



R⁷ and R¹⁰ are taken together to form

n3 is 1 and R¹¹ is H;

Z is O or a bond;

n5 is 0; and

5 Y is CO, CH₂, or a bond;

or a pharmaceutically acceptable salt thereof.

According to a fourth more preferred embodiment of said second preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein:

10 R¹ is N(R²⁴R²⁵);

n1 is 0;


n3 is 1;

n4 is 0;

n5 is 0;

15 Y is CO or CS;



Z is a bond; and



R³ and R¹¹ are taken together to form

or a pharmaceutically acceptable salt thereof.

20 According to a fifth more preferred embodiment of said second preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein:



R⁶ and R¹⁰ are taken together to form

5 n₃ is 1 and R¹¹ is H;

n₅ is 0;

Y is CO or CH₂; and

Z is O or a bond;

or a pharmaceutically acceptable salt thereof.

10 According to a third preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein said compound is:

8-butyl-7-(3-(imidazol-5-yl)-1-oxopropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

15 8-butyl-2-(2-hydroxyphenyl)-7-(imidazol-4-yl-propyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-7-(4-imidazolylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

20 7-(2-(imidazol-4-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(1-oxo-2-(1-(phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

- 7-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
 7-((1H-imidazol-4-yl)methyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
 5 7-((4-imidazolyl)carbonyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
 7-(1-(4-cyanophenylmethyl)-imidazol-5-yl)methyl-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
 7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;
 10 5-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
 6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;
 15 6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;
 5-butyl-7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
 7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
 20 5-butyl-7-(2-(1H-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;
 7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-(phenylmethoxy)-phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or
 25 2-(2-butoxyphenyl)-7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;
 or a pharmaceutically acceptable salt thereof.

According to a fourth preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein said
 30 compound is:

1,2-dihydro-1-((1H-imidazol-4-yl)methyl)-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

5 9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-Chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-Bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-
10 dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

or a pharmaceutically acceptable salt thereof.

According to a more preferred embodiment of said fourth preferred
15 embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein said compound is:

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-
20 dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-Chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-Bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

25 1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

According to a fifth preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein said compound is:

30

7-(2-amino-1-oxo-3-thiopropyl)-8-(mercaptoethyl)-2-(2-methoxyphenyl)-
5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide;
or a pharmaceutically acceptable salt thereof.

According to a sixth preferred embodiment of the first aspect of the invention
5 said farnesyl transferase inhibitor is a compound according to formula I, wherein said
compound is:

5-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6-dihydro-2-
phenyl-1H-imidazo[1,2-a][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.


10 According to a seventh preferred embodiment of the first aspect of the
invention said farnesyl transferase inhibitor is a compound according to formula I,
wherein said compound is:







1,2-dihydro-1-(2-(imidazol-1-yl)-1-oxoethyl)-4-(2-methoxyphenyl)
imidazo[1,2a][1,4]benzodiazepine;

15 1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-3-yl)-1-oxoethyl)
imidazo[1,2a][1,4]benzodiazepine; or


1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-4-yl)-1-oxoethyl)
imidazo[1,2a][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.







20 According to an eighth preferred embodiment of the first aspect of the
invention said farnesyl transferase inhibitor is a compound according to formula I,
wherein said compound is:













5

















or a pharmaceutically acceptable salt thereof.

According to a ninth preferred embodiment of the first aspect of the invention
 5 said farnesyl transferase inhibitor is a compound according to formula I, wherein said
 compound is:








or a pharmaceutically acceptable salt thereof.

- 5 According to a first more preferred embodiment of said ninth preferred embodiment of the first aspect of the invention said farnesyl transferase inhibitor is a compound according to formula I, wherein said compound is:



or a pharmaceutically acceptable salt thereof.

- 10 A second more preferred embodiment of said ninth preferred embodiment comprises said first more preferred embodiment of said eighth preferred embodiment wherein said anthracyclin is doxorubicin, daunorubicin, epirubicin, idarubicin, or amrubicin, or a pharmaceutically acceptable salt thereof.

- 15 A third more preferred embodiment of said ninth preferred embodiment comprises said second more preferred embodiment of said eighth preferred embodiment wherein said anthracyclin is doxorubicin, or a pharmaceutically acceptable salt thereof.

- 20 In a preferred embodiment of the first aspect of the invention, and of each of said first through ninth preferred embodiments of said first aspect of the invention, and of each of said more preferred embodiments thereof, termed the tenth preferred embodiment of said first aspect of the invention, said anthracycline is doxorubicin, daunorubicin, epirubicin, idarubicin, or amrubicin, or a prodrug thereof, or a pharmaceutically acceptable salt of said anthracyclin or of said anthracyclin prodrug.

In a more preferred embodiment of said tenth preferred embodiment, said anthracyclin is doxorubicin, or a pharmaceutically acceptable salt thereof.

In a second aspect the present invention features a pharmaceutical composition according to said first aspect of the invention, or according to any one of said preferred embodiments of said first aspect, or according to any one of said more preferred embodiments of said first aspect, and a pharmaceutically acceptable carrier, vehicle or diluent.

In a third aspect the present invention features a method of decreasing the rate of proliferation of nasopharyngeal carcinoma cells, said method comprising contacting said nasopharyngeal cells with a farnesyl transferase inhibiting compound in combination with an anthracycline compound, separately or simultaneously, wherein each of said farnesyl transferase inhibiting compound and said anthracycline compound is selected from the farnesyl transferase inhibiting compounds the anthracycline compounds disclosed in the pharmaceutical compositions according to said first aspect of the invention, or according to any one of said preferred embodiments of said first aspect, or according to any one of said more preferred embodiments of said first aspect.

In a first preferred embodiment of said third aspect the present invention features a method of decreasing the rate of proliferation of nasopharyngeal carcinoma cells, said method comprising contacting said nasopharyngeal cells with a pharmaceutical composition according to said first aspect of the invention, or according to any one of said preferred embodiments of said first aspect, or according to any one of said more preferred embodiments of said first aspect

In a second preferred embodiment of said third aspect the present invention features a method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient a pharmaceutical composition according to said first aspect of the invention, or according to any one of said preferred embodiments of said first aspect, or according to any one of said more preferred embodiments of said first aspect.

In a third preferred embodiment of said third aspect the present invention features a method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient effective amounts of one or more farnesyl transferase inhibitor in combination with one or more anthracycline, wherein said
5 effective amounts of said farnesyl transferase inhibitor or inhibitors and of said anthracyclin or anthracyclines are effective in combination to treat said nasopharyngeal carcinoma.

In a fourth preferred embodiment of said third aspect, the invention features a method according to any one of said first, second or third preferred embodiments of
10 said fourth preferred embodiments wherein said patient is a mammal.

In a fifth preferred embodiment of said third aspect, the invention features a method according to any one of said first, second, third or fourth preferred embodiments of said third aspect wherein said patient is a human being.

In a sixth preferred embodiment of said third aspect, the invention features a
15 method according to any one of said first, second, third, fourth or fifth preferred embodiments of said third aspect wherein a farnesyl transferase inhibitor and an anthracycline are administered substantially simultaneously.


In a fourth aspect the invention features a pharmaceutical kit comprising one or more of a farnesyl transferase inhibitor or pharmaceutically acceptable salt thereof
20 and one or more of an anthracycline or pharmaceutically acceptable salt thereof and instructions for use for the treatment of nasopharyngeal carcinoma.

In a first preferred embodiment of said fourth aspect of the invention features a kit comprising: a) a first unit dosage form comprising a farnesyl transferase inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said farnesyl transferase
25 inhibitor or of said farnesyl transferase inhibitor prodrug and a pharmaceutically acceptable carrier, vehicle or diluent; b) a second unit dosage form comprising an

anthracycline, a prodrug thereof or a pharmaceutically acceptable salt of said anthracycline or of said anthracycline prodrug and a pharmaceutically acceptable carrier, vehicle or diluent; and c) a container.

In a more preferred embodiment of said first preferred embodiment of said fourth aspect of the invention is featured a kit wherein said farnesyl transferase inhibitor comprises a compound according to formula I or a pharmaceutically acceptable salt thereof, and said anthracycline comprises doxorubicin, daunorubicin, epirubicin, idarubicin, or amrubicin or a pharmaceutically acceptable salt thereof.

In a still more preferred embodiment of said first preferred embodiment of said fourth aspect of the invention is featured a kit wherein said farnesyl transferase inhibitor comprises a compound according to the formula:



or a pharmaceutically acceptable salt thereof, and said anthracycline comprises doxorubicin or a pharmaceutically acceptable salt thereof.

The disclosure of International Patent Application Publication No. WO 00/39130 teaches one or more methods of synthesizing compounds according to formula I.

According to another preferred aspect, the present invention relates to a drug combination comprising at least one anthracycline compound and at least one farnesyl transferase inhibitor compound, wherein said farnesyl transferase inhibitor compound is described in one or more of the following United States patents, the disclosure of each of which is hereby incorporated by reference in its entirety: 6,455,523, 6,451,812, 6,441,017, 6,440,989, 6,440,974, 6,436,960, 6,432,959, 6,426,352, 6,410,541, 6,403,581, 6,399,615, 6,387,948, 6,387,905, 6,387,903, 6,384,061, 6,376,496, 6,372,747, 6,362,188, 6,358,970, 6,358,968, 6,342,487, 6,329,376,

6,316,462, 6,300,501, 6,297,249, 6,294,552, 6,277,854, 6,268,394, 6,268,378,
 6,265,382, 6,262,110, 6,258,824, 6,248,756, 6,242,458, 6,239,140, 6,228,865,
 6,228,856, 6,225,322, 6,218,406, 6,218,401, 6,214,828, 6,214,827, 6,211,193,
 6,194,438, 6,187,786, 6,174,903, 6,172,076, 6,160,015, 6,159,984, 6,156,746,
 5 6,150,377, 6,146,842, 6,143,758, 6,127,390, 6,127,366, 6,124,295, 6,103,723,
 6,103,487, 6,093,737, 6,090,948, 6,090,944, 6,080,870, 6,080,769, 6,077,853,
 6,075,025, 6,071,935, 6,071,907, 6,066,738, 6,066,648, 6,063,930, 6,060,038,
 6,054,466, 6,051,582, 6,051,574, 6,048,861, 6,040,311, 6,040,305, 6,039,683,
 6,030,982, 6,028,201, 6,017,926, 6,015,817, 6,013,662, 6,001,835, 5,998,407,
 10 5,994,364, 5,990,277, 5,985,879, 5,981,562, 5,977,134, 5,977,128, 5,972,984,
 5,972,966, 5,972,942, 5,968,965, 5,965,609, 5,965,578, 5,965,570, 5,962,243,
 5,958,940, 5,958,939, 5,958,890, 5,952,473, 5,948,781, 5,945,430, 5,945,429,
 5,939,557, 5,939,439, 5,939,416, 5,932,590, 5,929,077, 5,925,651, 5,925,648,
 5,925,639, 5,922,883, 5,919,785, 5,914,341, 5,891,872, 5,885,995, 5,883,105,
 15 5,880,140, 5,880,128, 5,877,177, 5,876,951, 5,874,452, 5,874,442, 5,872,136,
 5,872,135, 5,869,682, 5,869,275, 5,861,395, 5,859,035, 5,859,015, 5,859,012,
 5,856,439, 5,856,326, 5,854,265, 5,854,264, 5,852,034, 5,852,010, 5,849,724,
 5,837,224, 5,821,118, 5,817,678, 5,807,853, 5,807,852, 5,801,175, 5,789,438,
 5,780,492, 5,780,488, 5,773,273, 5,756,528, 5,753,650, 5,736,539, 5,734,013,
 20 5,728,703, 5,721,236, 5,712,280, 5,710,171, 5,703,241, 5,703,090, 5,703,067,
 5,686,472, 5,684,013, 5,672,611, 5,663,193, 5,661,161, 5,661,152, 5,661,128,
 5,652,257, 5,635,363, 5,631,280, 5,627,202, 5,624,936, 5,585,359, 5,578,629,
 5,576,313, 5,576,293, 5,571,835, 5,567,729, 5,536,750, 5,534,537, 5,525,479,
 5,523,456, 5,510,371, 5,504,212, 5,504,115, 5,491,164, and 5,480,893.

25 According to another preferred aspect, the present invention relates to a drug
 combination comprising at least one anthracycline compound and at least one farnesyl
 transferase inhibitor compound, wherein said farnesyl transferase inhibitor compound
 is described in one or more of the following United States patent publications, the
 disclosure of each of which is hereby incorporated by reference in its entirety:
 30 20020136744, 20020128287, 20020120145, 20020119981, 20020107226,
 20020103207, 20020086884, 20020077301, 20020068742, 20020052380,

20020037889, 20020037888, 20020022633, 20020019530, 20020019400,
20020010184, 20020010176, 20020006967, 20010053853, 20010049113,
20010044938, 20010039283, 20010039273, 20010016585, 20010014681, and
20010007870.

5 According to yet another preferred aspect, the present invention relates to a
drug combination comprising at least one anthracycline compound and at least one
farnesyl transferase inhibitor compound, wherein said farnesyl transferase inhibitor
compound is described in one or more of the following international patent
10 applications and publications, the disclosure of each of which is hereby incorporated
by reference in its entirety: WO02064142, , WO02056884, WO02051835,
WO02051834, WO0244164, WO0243733, WO0242296, WO0240015, WO0234247,
WO0228409, WO0228381, WO0224687, WO0224686, WO0224683, WO0224682,
WO0218368, WO0198302, WO0181322, WO0179180, WO0179179, WO0164252,
WO0164246, WO0164226, WO0164218, WO0164217, WO0164199, WO0164198,
15 WO0164197, WO0164196, WO0164195, WO0164194, WO0162727, WO0162234,
WO0160815, WO0160458, WO0160369, WO0160368, WO0156552, WO0151494,
WO0146138, WO0146137, WO0136395, WO0109127, WO0109125, WO0109124,
WO0109112, WO0107437, WO0078363, WO0070083, WO0064891, WO0061145,
WO0052134, WO0051612, WO0051611, WO0051547, WO0041992, WO0039716,
20 WO0039119, WO0039082, WO0037459, WO0037458, WO0037076, WO0034239,
WO0031064, WO0027803, WO0016778, WO0012543, WO0006748, WO0001691,
WO0001678, WO0001674, WO0001411, WO0001386, WO9958132, WO9955725,
WO9943314, WO9941235, WO9938862, WO9933834, WO9932114, WO9928315,
WO9928314, WO9928313, WO9927933, WO9927929, WO9927928, WO9920612,
25 WO9920611, WO9920609, WO9918951, WO9910525, WO9910524, WO9910523,
WO9910329, WO9909985, WO9906580, WO9905117, WO9901434, WO9900654,
WO9857970, WO9857968, WO9857965, WO9857963, WO9857962, WO9857961,
WO9857960, WO9857959, WO9857955, WO9857950, WO9857949, WO9857948,
WO9857947, WO9857946, WO9857945, WO9857944, WO9857654, WO9857633,
30 WO9844797, WO9843629, WO9840383, WO9834921, WO9832741, WO9830558,
WO9829390, WO9829119, WO9828980, WO9820001, WO9817629, WO9811106,

WO9811100, WO9811099, WO9811098, WO9811097, WO9811096, WO9811093,
WO9811092, WO9811091, WO9809641, WO9807692, WO9804545, WO9802436,
WO9749700, WO9745412, WO9744350, WO9743437, WO9738665, WO9738664,
WO9736901, WO9736900, WO9736898, WO9736897, WO9736896, WO9736892,
5 WO9736891, WO9736890, WO9736889, WO9736888, WO9736886, WO9736881,
WO9736879, WO9736877, WO9736876, WO9736875, WO9736605, WO9736593,
WO9736592, WO9736591, WO9736587, WO9736585, WO9736584, WO9736583,
WO9730992, WO9730053, WO9727854, WO9727853, WO9727852, WO9727752,
WO9723478, WO9721701, WO9718813, WO9716443, WO9706138, WO9705902,
10 WO9705270, WO9703050, WO9703047, WO9702817, WO9701275, WO9639137,
WO9637204, WO9635707, WO9634010, WO9631525, WO9631501, WO9631477,
WO9630343, WO9630015, WO9630014, WO9625512, WO9624612, WO9624611,
WO9622278, WO9617861, WO9617623, WO9610037, WO9610035, WO9610034,
WO9610011, WO9609836, WO9609821, WO9609820, WO9606609, WO9534535,
15 WO9532191, WO9526981, WO9525092, WO9520396, WO9512612, WO9511917,
WO9509001, WO9509000, WO9500497, WO9426723, WO9419357, WO9418157,
WO9410184, WO9410138, WO9410137, WO9409766, WO9407485, WO9404561,
WO9402134, WO9400419, and WO9116340. Particularly preferred are the farnesyl
transferase inhibitor compounds described in the following international patent
20 applications and publications: WO00/39130, WO98/00409, WO99/65922,
WO99/65898, WO99/64401, and PCT/US01/23959.

According to yet another preferred aspect, the present invention relates to a
drug combination comprising at least one anthracycline compound and at least one
farnesyl transferase inhibitor compound, wherein said anthracycline compound is
25 described in one or more of the following United States patents, the disclosure of each
of which is hereby incorporated by reference in its entirety: 6,437,105, 6,433,150,
6,403,563, 6,284,738, 6,284,737, 6,245,358, 6,194,422, 6,187,758, 6,184,374,
6,184,365, 6,160,102, 6,107,285, 6,103,700, 6,087,340, 6,080,396, 5,977,082,
5,965,407, 5,958,889, 5,948,896, 5,945,518, 5,942,605, 5,843,903, 5,801,257,
30 5,789,386, 5,776,458, 5,744,454, 5,719,130, 5,710,135, 5,593,970, 5,587,495,
5,532,218, 5,294,701, 5,260,425, 5,242,901, 5,220,001, 5,212,291, 5,196,522,

5,162,512, 5,124,318, 5,124,317, 5,122,368, 5,091,373, 5,091,372, 5,045,534,
5,004,606, 5,003,055, 4,997,922, 4,965,352, 4,959,460, 4,952,566, 4,950,738,
4,948,880, 4,946,831, 4,918,173, 4,918,172, 4,914,191, 4,897,470, 4,870,058,
4,863,739, 4,855,414, 4,840,938, 4,839,346, 4,833,241, 4,795,808, 4,772,688,
5 4,734,493, 4,713,371, 4,710,564, 4,697,005, 4,675,311, 4,663,445, 4,642,335,
4,632,922, 4,612,371, 4,591,636, 4,564,674, 4,563,444, 4,562,177, 4,550,159,
4,537,882, 4,534,971, 4,526,960, 4,522,815, 4,474,945, 4,472,571, 4,465,671,
4,439,603, 4,438,105, 4,424,342, 4,419,348, 4,411,834, 4,409,391, 4,405,713,
4,405,522, 4,401,812, 4,393,052, 4,387,218, 4,385,122, 4,383,037, 4,373,094,
10 4,366,149, 4,360,664, 4,355,026, 4,351,937, 4,337,312, 4,327,029, 4,325,946,
4,322,412, 4,309,503, 4,303,785, 4,293,546, 4,267,312, 4,264,510, 4,263,428,
4,259,476, 4,247,545, 4,245,045, 4,244,880, 4,215,062, 4,209,588, 4,207,313,
4,192,915, 4,166,848, 4,138,480, 4,134,903, 4,133,877, 4,127,714, 4,067,969, and
3,963,760.

15 According to yet another preferred aspect, the present invention relates to a
drug combination comprising at least one anthracycline compound and at least one
farnesyl transferase inhibitor compound, wherein said anthracycline compound is
described in one or more of the following United States patent publications, the
disclosure of each of which is hereby incorporated by reference in its entirety:
20 20020137694, 20020077303, and 20010053845.

According to still yet another preferred aspect, the present invention relates to
a drug combination comprising at least one anthracycline compound and at least one
farnesyl transferase inhibitor compound, wherein said anthracycline compound is
described in one or more of the following international patent applications and
25 publications, the disclosure of each of which is hereby incorporated by reference in its
entirety: WO0187814, WO0164197, WO0076525, WO0066093, WO0056267,
WO0044762, WO0027404, WO0026223, WO0015203, WO9966918, WO9958543,
WO9957126, WO9952921, WO9948503, WO9945015, WO9935153, WO9931140,
WO9929708, WO9908687, WO9846598, WO9840104, WO9839337, WO9802446,
30 WO9749433, WO9749390, WO9740057, WO9733897, WO9729191, WO9719954,
WO9712895, WO9700880, WO9639121, WO9629335, WO9607665, WO9524412,

WO9516695, WO9516693, WO9509173, WO9426311, WO9420114, WO9405259, WO9313804, WO9305774, WO9216629, WO9210212, WO9207866, WO9119725, WO9105546, WO9010639, WO9004601, WO9001490, WO9000173, WO8911532, WO8809823, WO8809166, WO8703481, WO8203769 and WO8002112.

5 According to a more preferred aspect, the present invention relates to drug combinations comprising at least one farnesyl transferase inhibitor compound described in International Patent Publication No. WO 00/39130 with an anthracycline. Among the anthracyclines, doxorubicin, daunorubicin, epirubicin, idarubicin, and amrubicin are preferred, and doxorubicin is most preferred. The disclosure of
10 International Patent Publication No. WO 00/39130 is specifically incorporated herein by reference in its entirety.

In a particularly preferred embodiment the invention features a drug combination comprising Compound A and doxorubicin.

As a result of their mechanism of action, the farnesyl transferase inhibitor
15 compounds, especially the compounds mentioned above, in general have a cytostatic-type activity.

In employing the drug combinations according to the invention comprising at least one farnesyl transferase inhibitor and at least one anthracycline a goal is to obtain an increased anti-cancer activity, such as, for example, a prolonged stabilization of the
20 size of the tumor, or a tumor regression.

According to the present invention, a composition is active if after its administration, it inhibits, retards or prevents the proliferation of tumor cells. Thus an advantageous characteristic of a pharmaceutical composition comprising a drug combination according to the invention can be an increase in the delay of tumor
25 growth.

The drug combinations according to the present invention can advantageously prolong or maintain the anticancer activity of either the anthracycline compound or the farnesyl transferase compound, in comparison with the activities obtained with each of the anthracycline compound or the farnesyl transferase compound considered
30 in isolation.

A further advantage of the combinations according to the present invention relates to toxicity. Specifically, the therapeutic synergy of the combinations allows for lower dosages of one or both of the components relative to the dosages that would be required to achieve the same level of therapeutic activity if the components were administered individually.

The term "prodrug" refers to a pharmaceutically acceptable metabolic precursor of a drug of interest; i.e., a compound or composition which is converted to an active form of a desired drug in the body.

Certain abbreviations are used herein, as follows:

10	EBERs	EBV-encoded RNAs
	EBNA1	Epstein-Barr nuclear antigen 1
	EBV	Epstein-Barr virus
	Ftase	farnesyl-transferase
	GGTase	geranylgeranyl-transferase
15	FTI	farnesyltransferase inhibitors
	LMP1	latent membrane protein 1
	NPC	nasopharyngeal carcinoma
	TRAF	TNF-receptor associated factor

The anthracycline compound and the farnesyl transferase inhibiting compound which form the drug combination of the invention can be administered simultaneously, separately or sequenced over time, it being possible to adapt this frequency so as to obtain the maximum efficacy of the combination and, for each administration, to have a variable duration ranging from a rapid total administration to a continuous perfusion. The compounds which form the combination can be administered at different rates, can be administered independently according to schemes chosen from the continuous, intermittent, repeated, alternated or sequential schemes, and can be repeated a number of times per day.

Advantageously, the farnesyl transferase inhibitor having a cytostatic activity can be administered according to a continuous scheme. More advantageously, this scheme allows the plasma levels to be maintained higher than or equal to the concentration necessary to inhibit 50% of the growth of the cells (IC₅₀), e.g., as

determined in the in-vitro cell viability assay described herein. Advantageously, the anthracycline can be administered according to a scheme dependent on the type of tumor model; preferably according to an intermittent scheme.

It follows from the foregoing that the drug combinations of the present invention are not limited to those which are obtained by physical association of the constituents, but also to those which allow a separate administration which can be simultaneous or spread out over time. Thus the constituents can be administered independently according to distinct methods and routes including, without limitation, the oral, intraperitoneal, parenteral, intravenous, topical, rectal, vaginal, and respiratory mucosa routes.

Advantageously, the farnesyl transferase inhibitor and anthracycline constituents of the combinations according to the invention are administered orally; most preferably, the farnesyl transferase inhibitor and anthracycline constituents of the drug combinations according to the invention are bioavailable by the oral route.

Also advantageously, the farnesyl transferase inhibitor and anthracycline constituents of the drug combinations according to the invention may be administered intravenously.

Also advantageously, the farnesyl transferase inhibitor constituents may be administered orally and the anthracycline constituents may be administered intravenously, or vice versa.

The products for intravenous injection are generally pharmaceutically acceptable sterile solutions or suspensions which optionally can be prepared extemporaneously at the time of use. For the preparation of non-aqueous solutions or suspensions, natural vegetable oils can be used such as olive oil, sesame oil or paraffin oil or injectable organic esters such as ethyl oleate. The sterile aqueous solutions can be formed of a solution of one or both of the anthracycline compound and the farnesyl transferase inhibiting compound in water. The aqueous solutions are suitable for intravenous administration inasmuch as the pH is suitably adjusted and the isotonicity is produced, for example, by a sufficient quantity of sodium chloride or of glucose. Sterilization can be carried out by heating or by any other means which does not

adversely affect the composition. The drug combinations can also be present in the form of liposomes or in combination form with supports such as cyclodextrins or polyethylene glycol's.

As solid compositions for oral administration, compressed tablets, pills, 5 powders (gelatin capsules, cachets) or granules can be used. In these compositions, one or both of the anthracycline compound and the farnesyl transferase inhibiting compound is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a current of argon. These compositions can likewise comprise substances other than the diluents, for example one or more lubricants such as 10 magnesium stearate or talc, a colorant, a coating (coated tablets) or a lacquer.

As liquid compositions for oral administration, it is possible to use pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs comprising inert diluents such as water, ethanol, glycerol, vegetable oils or paraffin oil. These compositions can comprise substances other than the diluents, for example 15 wetting, sweetening, thickening, flavoring or stabilising products.

The compositions for rectal administration are suppositories or rectal capsules which contain, apart from one or both of the anthracycline compound and the farnesyl transferase inhibiting compound, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.

20 The compositions for topical administration can be, for example, creams, lotions, eye lotions, mouthwashes nasal drops or aerosols.

Generally speaking, the physician will determine the appropriate dosage of each of the anthracycline compound and the farnesyl transferase inhibiting compound as a function of the age, weight and all the other factors individual to the subject to be 25 treated. Generally the doses depend on the effect sought, the duration of the treatment and the route of administration used. Doses generally range, as far as the farnesyl transferase inhibitor is concerned, from 10 mg to 2000 mg per day by the oral route for an adult with unit doses ranging from 50 mg to 1000 mg of active substance; and as far as the anthracyclines are concerned: from 10 mg to 1000 mg of active substance 30 per day by the intravenous route for an adult. The treatment can be repeated a number

of times per day or per week as determined appropriate by the physician. Preferably the treatment is continued until a stabilisation, a partial remission, a total remission or a recovery is achieved.

In the combinations according to the invention for which the administration of the constituents can be simultaneous, separated or spread out over time, it is particularly advantageous that the quantity of the farnesyl transferase inhibitor compound is from 10 to 90% by weight of the combination, it being possible for this content to vary as a function of the nature of the associated substance, the efficacy sought and the nature of the cancer cells to be treated.

The drug combinations according to the invention can be utilized for the treatment of diseases connected with malignant or benign cell proliferations of the cells of various tissues and/or organs, comprising the muscle, bone or connective tissues, the skin, the brain, the lungs, the sex organs, the lymphatic or renal systems, the mammary or blood cells, the liver, the digestive apparatus, the colon, the pancreas and the thyroid or adrenal glands, and including the following pathologies: psoriasis, restenosis, different types of sarcomas such as Kaposi's sarcoma, cancers of the head and of the neck, the pancreas, the colon, the lung, the ovary, the breast, the brain, the prostate, the liver, the stomach, the bladder, the kidney, the prostate or the testicles, Wilm's tumor, teratocarcinomas, cholangiocarcinoma, choriocarcinoma, melanomas, cerebral tumors such as neuroblastoma, gliomas, multiple myelomas, leukemias and lymphomas such as chronic lymphocytic leukemias, acute or chronic granulocytic lymphomas, and Hodgkin's disease.

The combinations according to the invention can be particularly useful for the treatment of cancers such as cancers of the pancreas, the colon, the lung, the ovary, the breast, the brain, the prostate, the liver, the stomach, the bladder or the testicles, and of the head and neck, and more advantageously cancer of the head and neck. In a particularly preferred embodiment of the invention a combination according to the invention is used for the treatment of nasopharyngeal carcinoma.

In particular, the drug combinations of the invention have the advantage of being able to employ the anthracycline compound and/or the farnesyl transferase inhibiting compound in doses which are lower than those in which either compound is used alone.

5 Thus the present invention relates to the use of combinations comprising at least one farnesyl transferase inhibitor and at least one anthracycline for the preparation of medicaments useful for the treatment of the above mentioned pathologies; advantageously cancers, most advantageously nasopharyngeal carcinoma. Further the present invention relates to the use of drug combinations comprising at
10 least one farnesyl transferase inhibitor and at least one anthracycline for the preparation of medicaments for administration which is simultaneous, separate or sequenced over time.

 The farnesyl transferase inhibitor compounds referenced herein can be prepared by means commonly known to those skilled in the art, as evidenced by the
15 patents already specifically incorporated by reference herein. Likewise the anthracycline compounds can be prepared by means well-known in the art.

 The present invention is further illustrated by the following examples which are designed to teach those of ordinary skill in the art how to practice the invention. The following examples are merely illustrative of the invention and should not be
20 construed as limiting the invention as claimed.

BRIEF DESCRIPTION OF THE DRAWINGS

 Figure 1. Detection of the EBERs in NPC tumor lines and assessment of NPC cell proliferation *in vitro*. A and B: *in situ* hybridization of the EBERs on tissue
25 sections of xenografted tumors formed by C15 (A) and C666-1 (B) NPC cells. (scale bar: 20 μ M). C: Ki 67 immunostaining of C15 cells grown *in vitro* for 72 h on PolyHema matrix; cell aggregates (average size 150 μ M) were cytopsined and fixed in acetone (10 min/4°C) prior to immunostaining (scale bar : 10 μ m). D: Proliferation of
30 C15 (solid line) and C666-1 (dotted line) cells *in vitro* demonstrated by sequential WST-1 assays. Cells were seeded in 96 well plates at 10^5 /well on plastic coated with PolyHema (C15) and 35×10^3 /well without plastic coating (C666-1). The WST-1

reaction was performed at 24, 48 and 72 hours to assess the evolution of cell viability reflected by absorbance at 490 nm. Data are the means (\pm standard deviation) of quadruplicates. Similar results were obtained in three separate experiments.

Figure 2. Effect of Compound A, alone or in combination with doxorubicin, on NPC cell viability. C15 and C666-1 cells were grown in 96 well plates, in the presence of various concentrations of pharmacological agents, prior to assessment of cell viability using the WST-1 assay. The observed results are reported as means (\pm standard deviation) of quadruplicates and are representative of three similar experiments. A: treatment of NPC cells with various concentrations of Compound A alone. B: treatment of NPC cells with various concentrations of doxorubicin with or without Compound A, 5 μ M (C15) or 10 μ M (C666-1).

Figure 3. Induction of nuclear fragmentation in C15 cells treated by doxorubicin combined to Compound A. Nuclei were visualized by Hoechst 33342 staining (scale bar : 10 μ m). A: non-treated cells. B: cells treated for 48 hrs with doxorubicin (1 μ M) combined to Compound A (5 μ M); most nuclei shrank (arrows) and exhibited chromatin condensation and fragmentation (arrowheads).

Figure 4. Induction of caspase activation in C15 cells treated by doxorubicin combined to Compound A. C15 cells were treated with doxorubicin (1 μ M), Compound A (5 μ M) or a combination of both molecules for 48 h. Measurement of caspase activation was based on selective intra-cellular retention of a fluorescent caspase substrate inhibitor (VAD-fluoromethyl ketone labelled with carboxyfluorescein). Retention of the fluorescent substrate was assessed by flow cytometry in non-treated (grey line) or treated (black line) C15 cells.

Figure 5. Induction of PARP-cleavage in C15 cells treated by doxorubicin combined to Compound A. C15 cells were treated with doxorubicin (1 μ M), Compound A (5 μ M) or a combination of both for the indicated periods. Corresponding cell lysates (50 μ g protein per lane) were separated by 7.5% SDS-PAGE and analyzed by Western Blot with an anti-PARP monoclonal antibody. The cleaved product of PARP was at 85 kD, as shown in the positive-control extract derived from C15 cells treated with the CD95 agonist-antibody 7C11.

Figure 6. Induction of TRAF1-cleavage in C15 cells treated with doxorubicin combined to Compound A. A: Diagram of Fas-mediated TRAF-1-cleavage as reported by Leo et al. (2001). The locations of target peptides used for production of the H-3 monoclonal and H-132 polyclonal antibody are indicated by hatched boxes.

5 The peptide targeted by H-3 was entirely contained in fragment II whereas the peptide targeted by H132 was mainly co-linear with fragment I. B: C15 cells were treated for 24h with doxorubicin (1 μ M), Compound A (5 μ M) or a combination of both. Control cells were treated with the Fas-agonist antibody 7C11. Cell lysates (50 μ g protein per lane) were separated on a 8-16% SDS-PAGE linear gradient prior to Western Blot

10 analysis with anti-TRAF-1 antibodies. Both antibodies detected a main band at 46 kd. Additional bands corresponding to fragments of smaller sizes were visible, mainly in samples treated with 7C11 or the combination of doxorubicin and Compound A. In the extracts of cells treated with 7C11, these smaller fragments had apparent molecular weights of 29 kD (H-3) and 24 kD (H-132) which were compatible with the

15 sizes of TRAF1 fragments reported by Leo et al. (2001). Similar results were obtained in three similar experiments.

DETAILED DESCRIPTION OF THE INVENTION

Materials

20 Compound A and BIM-46068 were provided by Biomeasure, Incorporated (Milford, MA). FTI-277 and GGTI-286 were provided by Expansia (Aramon, France). Taxol, cis-platin, doxorubicin and 5-fluorouracyl were purchased from Sigma (Saint-Quentin Fallavier, France). C15 is an undifferentiated NPC tumor line propagated by sub-cutaneous passage into nude mice. (Busson, P., et al., Establishment and

25 characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer, 42 : 599-606, 88.) It was established from the biopsy of a primary nasopharyngeal tumor in a 13-year-old girl born in Morocco. The biopsy was collected prior to any therapeutic procedure, according to the institutional guidelines concerning the use of clinical material. This patient had a voluminous primary tumor

30 associated with lymph node and bone metastases and was treated by induction chemotherapy with a combination of vincristine, cyclophosphamide, doxorubicin and

5 methylprednisolone, prior to nasopharyngeal and cervical radiotherapy. A 70% tumor response was achieved in both the primary tumor and cervical lymph node metastases after two months of chemotherapy. Complete clinical remission was obtained after radiotherapy, however remission lasted only 5 months, due to recurrence of bone metastases. C15 cells express a wild type p53 protein. (Effert, P., et al., Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol, 66 : 3768-3775, 1992.)

10 C666-1 is an EBV-positive NPC cell line propagated *in vitro* related to an NPC xenograft, called xeno-666. (Cheung, S. T., et al., Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer, 83 : 121-126, 1999.) A primary *in vitro* culture was derived from xeno-666 at passage 18 and named C666. Subsequently, C666 was adapted to low density growth and several sub-clones were isolated. One of them, named C666-1, was extensively characterized and later used in this study. (*Id.*; Weinrib, L., et al., Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. Cancer Gene Ther, 8: 352-360., 2001.) C666-1 cells express a mutated p53 protein. (Weinrib, L., et al., Cancer Gene Ther, 8: 352-360., 2001.)

15 In situ hybridization of EBER's (EBV-encoded RNA's).

Pieces of xenografted C15 and C666-1 tumors were fixed (in a mix of acetic acid, formaldehyde and ethanol), paraffin-embedded and cut in 4 μ m sections. EBER's detection was performed by *in situ* hybridization with a mixture of peptide nucleic acid (PNA) probes reacting with both EBER 1 and 2 and labelled with fluorescein (Dako EBER-PNA probe, Dako, Trappes, France). The hybridization process was done as recommended by the manufacturer, using RNA's-free water. Hybridized probes were detected with anti-fluorescein antibodies conjugated to alkaline phosphatase (PNA ISH detection kit, Dako).

25 Preparation of NPC cells for *in vitro* experiments.

Prior to *in vitro* experiments, C15 xenografted tumors were minced and treated with type II collagenase for cell dispersion, as previously reported. (Sbih-Lammali, F., et al., Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res, 59 : 924-930, 1999.) Residual cell aggregates were removed by filtration on a nylon cell strainer

with 100 µm pores. C666-1 cells were permanently propagated *in vitro* in plastic flasks coated with collagen I (Biocoat, Becton-Dickinson, France). *In vitro* culture medium was Hepes-buffered RPMI with 5% fetal calf serum for both C15 and C666-1 cells. C666-1 cells which were derived from a single malignant clone were free of
5 contaminating murine fibroblasts. In contrast, C15 cell suspensions were often contaminated by murine fibroblasts. Therefore, for some experiments, C15 cell suspensions were grown on plastic coated with Poly(2-HydroxyEthylMethacrylate), an anti-adhesive polymer which inhibits cell attachment, (Fukazawa, H., et al., Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-
10 hydroxyethyl methacrylate)-coated surfaces. *Int J Cancer*, 67 : 876-882, 1996.), (PolyHEMA, Sigma, Saint-Quentin Fallavier, France). Using this coating procedure, fibroblast proliferation was completely inhibited whereas C15 cells grew as non-anchored spheroids or aggregates of 150 µm average diameter at 72 h (Fig. 1).

Ki 67 immunostaining.

15 C15 cell aggregates were deposited on glass slides by cytopinning, fixed in acetone at 4°C for 10 min and stained with a mouse monoclonal antibody against the KI 67 antigen (Dako, Trappes, France). This antibody is specific of the human antigen and does not cross-react with its murine counter-part. Immunoreactivity was detected with peroxidase conjugated antibodies (Power vision kit, ImmunoVision technologies,
20 Daly City, CA). Slides were counterstained with hematoxylin.

In vitro prenyl-transferase assays.

The effect of Compound A and other drugs on FTase activity was assayed *in vitro* with FTase from human brain cytosol (ABS Reagents, Wilmington, DE) as target enzyme and recombinant human H-Ras protein containing the wild type CAAX
25 box (Biomol, Plymouth Meeting, PA) as a specific substrate. The incubation mixture (25 µl) for [³H]-farnesylation contained 50 mM Tris-HCl (pH 7.5), 5 mM dithiothreitol, 20 µM ZnCl₂, 40 mM MgCl₂, 0.6 µM [³H]-farnesyl pyrophosphate (22.3 Ci /mmol) (NEN, Boston, MA), 4 µM recombinant H-Ras and 10 µg FTase. After 60 min at 37°C, the reaction was stopped by adding 150 µl of absolute ethanol.
30 The mixture was then filtered on Unifilter GF/B microplate (Packard, Rungis, France) and washed 6 times with ethanol prior to scintillation counting. After adding 50µl of

Microscint O, plates were counted with a Packard Top Count scintillation counter. Drug effects on GGTase I activity were assayed by a similar method with GGTase I from human brain (ABS reagent) as target enzyme and human recombinant H-Ras containing a mutated CAAX box (CVLL)(Biomol). The incubation mixture contained
5 4 μM recombinant H-Ras, 0.6 μM [^3H]-geranylgeranyl-pyrophosphate (19.3 Ci /mmol) (NEN) and 100 μg of GGTase I. GGTI-286 was used as a positive control for the GGTase-I inhibition assay. Results were expressed as the concentrations of drugs required to inhibit 50% of prenyl-incorporation into the recombinant H-Ras proteins (IC_{50}).

10 Assessment of farnesyl-transferase inhibition in intact cells.

The effect of Compound A on farnesyl-transferase in intact cells was assayed in MIA-Paca cells, a human pancreatic carcinoma cell line which was purchased from the ATCC. Both H-Ras and N-Ras were investigated as reference substrates of the endogenous farnesyl-transferase. Total protein extracts were prepared from MIA-Paca
15 cells treated for 48 h with increasing concentrations of Compound A (1-100 nM) along with extracts from untreated cells as a negative control. A positive control was provided by cells treated with mevastatine (30 μM). Mevastatine is an HMG-CoA reductase inhibitor which blocks the synthesis of farnesyl metabolic precursors. Cell extracts were separated by SDS-polyacrylamide gels (15%) and analyzed by Western
20 blot with polyclonal antibodies directed to H-Ras and N-Ras (Santa Cruz, Heidelberg, Germany). Farnesyl-transferase inhibition was assessed indirectly by detection of non-prenylated forms of H-Ras and N-Ras which were slightly shifted toward higher molecular weights and reacted more efficiently with antibodies.

Assessment of drug effect on NPC cell viability.

25 Cell viability assays were performed in 96 well plastic microplates, either uncoated (C666-1) or coated with Poly HEMA (C15). For each cell line, the number of cells distributed per well was optimized in order to achieve the highest metabolic activity while keeping exponential growth till the end of the test. C15 and C666-1 cells were seeded at 10^5 and 35×10^3 /well, respectively, in 150 μl culture medium.
30 Following an overnight pre-incubation culture, serial dilutions of chemotherapy drugs (50 μl ; final concentration 50 nM - 50 μM) were added in quadruplicate to a final

volume of 250 μ l. At the completion of a 72 h incubation with tested pharmacological agents, cell viability was evaluated using the WST-1 assay (Roche Molecular, France). The WST-1 assay is based on the cleavage of the tetrazolium salt by mitochondrial dehydrogenases. In contrast with other tests, it does not require washing
5 the cells in microplate wells and is compatible with spheroid culture. Cells were incubated with 10 μ l of the WST-1 reagent added to the culture medium, for 3 to 6 h, at 37°C. The plates were subsequently read on an ELISA reader (Dynatech MR7000, Guernsey channel Island, USA) using a 490 nm filter. The mean and standard deviation were determined for quadruplicate samples. For each compound, values
10 falling in the linear part of sigmoid curve were included in a linear regression analysis and were used to estimate the 50% inhibitory concentration (IC 50).

Measurement of caspase activity in drug treated NPC cells.

Caspase activity was assessed at single cell level by flow cytometry using the CaspaTag kit according to manufacturer instructions (Quantum-Appligene, Illkirch,
15 France). This procedure involved a cell-permeable, general caspase inhibitor (VAD-fluoromethyl ketone) labelled with carboxyfluorescein. This fluorescent inhibitor irreversibly binds to active caspases and therefore is selectively retained in apoptotic cells. For apoptosis induction, C15 and C666-1 cells were seeded in 24 well plates at 10^6 and 3×10^5 cells/well respectively, pre-incubated overnight and treated with drugs
20 for 48 h. In this context, it was not possible to incubate C15 cells on PolyHEMA, because the resulting cell aggregates were not suitable for flow cytometry. In order to discriminate human malignant cells from contaminating murine fibroblasts, C15 cell suspensions were submitted to additional staining with an anti-human HLA (human leukocyte antigen) A, B, C directly conjugated to allo-Phyco-Cyanine (Becton
25 Dickinson, Meylan, France). In a first step, both C15 and C666-1 cells were incubated for 1 h at 37°C, in their culture plates, with fluorescent VAD-FMK, in 300 μ l of culture medium. Cells were then washed and trypsinized. C15 cells were further incubated with the anti-HLA antibody. Finally, both caspase and HLA fluorescence were analysed using a FACS calibur flow cytometer (Becton Dickinson, Franklin
30 Lakes, NJ).

Assessment of PARP (Poly(ADP-ribose)polymerase) and TRAF1 cleavage.

Whole cell extracts were prepared from drug-treated and control C15 and C666-1 cells in RIPA-SDS buffer. (Sbih-Lammali, F., et al., Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. *Cancer Res*, 59:924-930, 1999.) Thirty to fifty µg of total protein extract were submitted to electrophoresis on 7.5% (PARP) or 8-16% gradient (TRAF1) SDS-polyacrylamide gels. Separated proteins were transferred to Immobilon membranes (Millipore, France) which were probed with anti-PARP (Oncogene, Boston, MA) or anti-TRAF-1 (Santa Cruz, Heidelberg, Germany) antibodies revealed with horseradish peroxidase-conjugated antibodies (Amersham, Les Ulis, France). Detection was performed with the ECL chemiluminescence system (Amersham, Les Ulis, France). Two types of antibodies from Santa Cruz were used for study of TRAF1-cleavage: the monoclonal H-3 and the H-132 polyclonal; a positive control was provided by C15 cells treated for 24 h with the CD95-agonist antibody, 7C11 (Immunotech, Marseille, France).

Detection of EBER's in NPC tumor lines.

In order to check that both C15 and C666-1 retained latent EBV-infection, EBER's expression was detected by *in situ* hybridization in both tumor lines (Fig. 1 A and B) (C666-1 xenografted tumors were reformed by cell injection into nude mice at *in vitro* passage 40). As expected, EBER's staining was essentially nuclear. Most but not all malignant cells were positively stained, an observation which is consistent with previous reports about fresh NPC biopsies. (Wu, T. C., et al., Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. *Am J Pathol*, 138: 1461-1469, 1991.)

Assessment of C15 and C666-1 proliferation.

As previously reported, C666-1 cells consistently proliferated *in vitro*, growing as cell monolayers in various types of plastic vessels. (Cheung, S. T., et al., Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. *Int J Cancer*, 83 : 121-126, 1999.) In order to prevent increasing contamination

by murine fibroblasts, tumor-dispersed C15 cells were seeded in microplates coated with PolyHema matrix and grown as floating aggregates. These aggregated cells remained proliferating as demonstrated by immuno-cytological detection of the human Ki-67 antigen in a significant fraction of them (Fig. 1C). In addition, repeated
5 measurements of WST reduction during 3 consecutive days of culture demonstrated a consistent, steady increase of viable cells (Fig. 1D). C15 cell doubling time was estimated at 1.5 days. In the same plates, without plastic coating, the doubling time of C666-1 cells was about 3.5 days (Fig. 1D).

Short term cytotoxicity of conventional drugs applied on NPC cells *in vitro*.

10 Cis-platinum, bleomycine, 5FU, doxorubicine and taxol are among the drugs most frequently used in chemotherapy of NPC. (Ali, H. et al., Chemotherapy in advanced nasopharyngeal cancer. Oncology (Huntingt), 14:1223-1230, 2000.) Their short term cytotoxic effect was assessed *in vitro* on the C15 and C666-1 cells, using a cell viability assay based on WST reduction. Cultured cells were incubated in the
15 presence of various concentrations of each therapeutic agent for 72 hours. As shown Table I, both C15 and C666-1 were highly sensitive to doxorubicin at concentrations of below 1 μ M. C666-1 cells were also highly sensitive to taxol, whereas C15 cells were totally resistant to this drug. On the other hand, C15 was mildly sensitive to the cytotoxic effect of cis-platinum (1 μ M IC₅₀) whereas C666-1 cells were five times
20 more resistant. No significant effects of bleomycin or 5-FU were observed in either cell line at the concentrations tested.

Characterization of a farnesyl-transferase inhibitor

Although doxorubicin was very active on both C15 and C666-1, it was not observed to induce massive apoptosis in these cell lines at the concentrations tested.
25 Therefore it was postulated to use molecularly targeted agents, especially farnesyl-transferase inhibitors (FTIs) in combination with doxorubicin, to increase its cytotoxic effect and attempt to induce apoptosis. Compound A is a peptidomimetic FTI which had been designed to be highly selective of farnesyl-transferase. The biological activity of this compound was first assayed for its effect on the activity of
30 purified human prenyl-transferase and its inhibition of ras-processing in intact cells. Table II shows that Compound A is a potent inhibitor of human brain FTase *in vitro*.

The IC₅₀ value is in the nanomolar range and compares favourably with the tested known FTI compounds FTI-277 and BIM-46068. (Sun, J., et al., Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. *Cancer Res*, 55 : 4243-4247, 1995; Prevost, G. P., et al., Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068. *Int J Cancer*, 83 : 283-287, 1999.) It is noteworthy that in contrast to other tested FTIs, no activity on GGTase-I by Compound A was observed at concentrations of up to 100 µM thus showing its high selectivity for FTase. The effect of Compound A on protein-farnesylation was further assessed in intact MIAPaca cells which are prototype target cells for prenylation-inhibitors. H-Ras and N-Ras, which are classical substrates for farnesyl-transferases, are both expressed and non-mutated in MIAPaca cells. A significant inhibition of H-Ras and N-Ras farnesylation was obtained when cells were incubated with only 50 nM of Compound A for 48 h.

Enhancement of doxorubicin cytotoxic activity on NPC cells when used in combination with Compound A.

As shown in Figure 2A, Compound A had only limited toxicity on both C15 and C666-1 cells when it was used alone (IC₅₀= 10 µM). However, the cytotoxic effect of doxorubicin was dramatically enhanced when it was combined with Compound A. For C15 cells, a more than additive effect was obvious for doxorubicin concentrations of 500 nM or 1 µM with Compound A at 5 µM. For C666-1 cells a higher concentration of the FTI drug was required to obtain a synergistic effect with doxorubicin. Still, a more than additive effect was observed for doxorubicin concentrations of 1 and 2 µM. In contrast, enhanced cisplatin and bleomycin cytotoxicity was not observed by combination with Compound A at test concentrations .

Contribution of apoptosis to the cytotoxic effect of the doxorubicin/Compound A combination.

After 48 h incubation with the doxorubicin/Compound A combination, many C15 cells started to round up, retract their processes, and subsequently detach from culture dishes. Under nuclear staining with Hoechst 33342, typical changes related to nuclear apoptosis - nuclear condensation and fragmentation - were detected at 48 h of incubation and became more obvious after 72 h. Such morphological changes were much less apparent in C15 cells treated with doxorubicin or Compound A alone. In contrast to C15 cells, significant changes in the morphology of the nucleus were not observed in C666-1 cells, even in the presence of both doxorubicin and Compound A, although some nuclei with partial chromatin condensation were recorded. Apoptosis of C15 cells under treatment by both drugs was further demonstrated by flow cytometry analysis of caspase activation which was obvious after a 48 h period of treatment. Finally PARP cleavage was analysed by Western blot in protein extracts of C15 cells treated by one drug or the association of both. A strong PARP cleavage was apparent after only a 24 h period of combined treatment. At 48 h, the intact fragment of the PARP was almost undetectable. Moderate PARP cleavage was also detected in cells treated by doxorubicin or Compound A alone, but a much lower fraction of the protein was affected in these experimental conditions. No caspase-activation and PARP cleavage were detected in C666-1 cells even when treated by doxorubicin combined with Compound A.

Cleavage of TRAF1 in C15 cells treated by the Compound A-doxorubicin combination.

NPC cells treated by doxorubicin and/or Compound A were investigated for TRAF1-cleavage. TRAF1 is a signalling adapter which has a restricted tissue distribution but whose expression is ectopically induced by EBV-infection. (Mosialos, G., et al., The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 80 : 389-399, 1995.) It has been reported that TRAF1 is strongly expressed by EBV-positive NPC cells. (Ardila-Osorio, H., et al., Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich

complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Int J Cancer, 81 : 645-649, 1999.) On the other hand, Leo et al. (2001) have reported that TRAF1 is cleaved at aspartate 163 in cells undergoing apoptosis, especially death receptor-mediated apoptosis but also doxorubicin-induced apoptosis. (Leo, E., et al., TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor- α induced apoptosis. J Biol Chem, 55: 8087-8093, 2000) C15 cells treated by a CD95-agonist (7C11) for 24 h were used as a positive control; a dramatic decrease in the amount of intact TRAF1 was observed in the corresponding protein extracts. Simultaneously, there was a marked increase of the cleaved fragments characterised by Leo et al., (*Id.*): fragment I (24 kD, reacting with the H-132 antibody) and II (30kD, reacting with H-3). In cells treated with doxorubicin or Compound A alone, no modifications of the TRAF1 molecule were observed. In contrast, a substantial increase of cleaved fragments similar to fragments I and II were observed in the extracts of cells treated by the combination of doxorubicin and Compound A. There were some differences in the patterns of cleavage induced by the CD95-agonist and the drug combination. Despite the visualisation of cleaved fragments, the amount of intact TRAF1 molecule was only marginally reduced in drug-treated cells. Further the cleaved fragment II consistently had a slightly bigger size than with the 7C11 agonist. TRAF1 was also detected in C666-1 cells and, although readily cleaved under treatment by the CD95-agonist, it was not cleaved under drug-treatment. This observation is consistent with the absence of apoptotic process.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents and other references mentioned herein are incorporated by reference.

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims.

Table I : Effects of conventional drugs on NPC cell viability *in vitro*. Determination of the IC₅₀.

	C15 Cells	C666-1 Cells
Doxorubicin	150 nM	200 nM
Cis-platinum	1 μ M	5 μ M
Bleomycin	5 μ M	5 μ M
5-fluorouracyl	5 μ M	5 μ M
Taxol	25 μ M	200 nM

5 - Data are the mean of quadruplicates. Similar results were obtained in three separate experiments.

10 Table II: Comparative assessment of FTase inhibitor action on purified human prenyl transferase activities.


	Enzyme assays IC ₅₀ (nM)	
	FTase	GGTase I
<i>BIM-46068</i>	91 (83- 99)	268000 (15200-384000)
<i>FTI-277</i>	30 (26- 34)	314 (305- 323)
<i>GGTI-286</i>	365 (329- 401)	114 (106- 123)
<i>Compound A</i>	15 (13 - 15)	> 100 μ M

- Assay results are reported as the mean of 2 experiments with the lowest and highest IC₅₀ values observed in individual experiments in parentheses.

CLAIMS

1. A pharmaceutical composition comprising a farnesyl transferase inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said farnesyl transferase inhibitor or of said farnesyl transferase inhibitor prodrug, and an anthracycline, a prodrug thereof or a pharmaceutically acceptable salt of said anthracycline or of said anthracycline prodrug.

2. A pharmaceutical composition according to claim 1, wherein said farnesyl transferase inhibitor is according to formula I:



wherein

n_1 is 0 or 1;


X is, independently for each occurrence, $(CHR^{11})_{n_3}(CH_2)_{n_4}Z(CH_2)_{n_5}$;

Z is O, $N(R^{12})$, S, or a bond;

n_3 is, independently for each occurrence, 0 or 1;

n_4 and n_5 each is, independently for each occurrence, 0, 1, 2, or 3;

Y is, independently for each occurrence, CO, CH_2 , CS, or a bond;



R^2 , R^{11} , and R^{12} each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl and aryl, wherein said optionally substituted moiety is optionally substituted with one or more of R^8 or R^{30} ;

R^3 is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more R^{30} ;

R^4 and R^5 each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₃₋₆)cycloalkyl, aryl, and heterocyclyl, wherein said optionally substituted moiety is optionally substituted with one or more R^{30} , wherein each said substituent is independently selected, or R^4 and R^5 can be taken together with the carbons to which they are attached to form aryl;

R^6 is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, -N(R^8R^9), -COOH, -CON(R^8R^9), and halo, where R^8 and R^9 each is, independently for each occurrence, H, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, aryl, or aryl(C₁₋₆)alkyl;

R^7 is, independently for each occurrence, H, =O, =S, or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₃₋₆)cycloalkyl, (C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₅₋₇)cycloalkenyl, (C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said optionally substituted moiety is


optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, -N(R⁸R⁹), -COOH, -CON(R⁸R⁹), and halo;

R¹⁰ is C;

or when n₁ = 0, R⁶ and R⁷ can be taken together with the carbon atoms to which they are attached to form aryl or cyclohexyl;

R²¹ is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl and aryl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of R⁸ and R³⁰;

R²² is H, (C₁₋₆)alkylthio, (C₃₋₆)cycloalkylthio, R⁸-CO-, or a substituent according to



the formula

R²⁴ and R²⁵ each is, independently for each occurrence, H, (C₁₋₆)alkyl, or aryl(C₁₋₆)alkyl;

R³⁰ is, independently for each occurrence, (C₁₋₆)alkyl, -O-R⁸, -S(O)_{n6}R⁸, -S(O)_{n7}N(R⁸R⁹),

-N(R⁸R⁹), -CN, -NO₂, -CO₂R⁸, -CON(R⁸R⁹), -NCO-R⁸, or halogen;


n₆ and n₇ each is, independently for each occurrence, 0, 1, or 2;

wherein said heterocyclyl is azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnoliny, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazoliny, imidazolyl, indoliny, indolyl, isochromanyl, isoindoliny, isoquinoliny, isothiazolidinyl, isothiazolyl, isothiazolidinyl,


morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, quinoxalyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydro-quinolyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, or thienyl; and

wherein said aryl is phenyl or naphthyl;
provided that:

when $n_1 = 1$, R^{10} is C and R^6 is H, then R^{10} and R^7 can be taken together to form




when $n_1 = 1$, R^{10} is C, and R^7 is =O, -H, or =S, then R^{10} and R^6 can be taken together



wherein X^1 , X^2 , and X^3 each is, independently, H, halogen, $-\text{NO}_2$, $-\text{NCO}-R^8$, $-\text{CO}_2R^8$, $-\text{CN}$, or $-\text{CON}(R^8R^9)$; and


when R^1 is $\text{N}(R^{24}R^{25})$, then n_3 is 1, n_4 and n_5 each is 0, Z is a bond, and R^3 and R^{11}



can be taken together to form
wherein n_2 is 1-6, and X^4 and X^5 each is, independently, H, (C_{1-6}) alkyl, or aryl,
or X^4 and X^5 can be taken together to form (C_{3-6}) cycloalkyl;

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition according to claim 2, wherein:




$N(R^{24}R^{25})$; and

X is $CH(R^{11})_{n3}(CH_2)_{n4}$ or Z, wherein when X is Z, Z is O, S, or $N(R^{12})$;

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition according to claim 3, wherein:




X is $CH(R^{11})_{n3}(CH_2)_{n4}$; and

$n1$ is 0;

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition according to claim 3, wherein:



$n3$, $n4$, and $n5$ each is 0;


Z is a bond;

Y is, independently for each occurrence, CO or CS; and

$n1$ is 0;


or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition according to claim 3, wherein:



R⁶ is H;

n₁ is 1;



R⁷ and R¹⁰ are taken together to form

n₃ is 1 and R¹¹ is H;

Z is O or a bond;

n₅ is 0; and

Y is CO, CH₂, or a bond;

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition according to claim 3, wherein:

R¹ is N(R²⁴R²⁵);

n₁ is 0;


n₃ is 1;

n₄ is 0;

n₅ is 0;

Y is CO or CS;


Z is a bond; and



R³ and R¹¹ are taken together to form

or a pharmaceutically acceptable salt thereof.


8. A pharmaceutical composition according to claim 3, wherein said farnesyl transferase inhibitor is a compound of formula I, wherein:



R¹ is

R⁷ is H or =O;

n₁ is 1;



R⁶ and R¹⁰ are taken together to form

n₃ is 1 and R¹¹ is H;

n₅ is 0;

Y is CO or CH₂; and

Z is O or a bond;

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:

8-butyl-7-(3-(imidazol-5-yl)-1-oxopropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-2-(2-hydroxyphenyl)-7-(imidazol-4-yl-propyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-7-(4-imidazolylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(imidazol-4-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(1-oxo-2-(1-(phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((1H-imidazol-4-yl)methyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((4-imidazolyl)carbonyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(1-(4-cyanophenylmethyl)-imidazol-5-yl)methyl-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

5-butyl-7-(2-(1H-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-(phenylmethoxy)-phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or

2-(2-butoxyphenyl)-7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:

1,2-dihydro-1-((1H-imidazol-4-yl)methyl)-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-Chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-Bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or
or a pharmaceutically acceptable salt thereof.

11. A combination according to claim 10, wherein said farnesyl transferase inhibitor is:

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-Chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-Bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

12. A combination according to claim 2, wherein said farnesyl transferase inhibitor is:

7-(2-amino-1-oxo-3-thiopropyl)-8-(mercaptoethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide;
or a pharmaceutically acceptable salt thereof.

13. A combination according to claim 2, wherein said farnesyl transferase inhibitor is:

5-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6-dihydro-2-phenyl-1H-imidazo[1,2-a][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.

14. A combination according to claim 2, wherein said farnesyl transferase inhibitor is:


1,2-dihydro-1-(2-(imidazol-1-yl)-1-oxoethyl)-4-(2-methoxyphenyl)imidazo[1,2a][1,4]benzodiazepine;







1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-3-yl)-1-oxoethyl)imidazo[1,2a][1,4]benzodiazepine; or








1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-4-yl)-1-oxoethyl)imidazo[1,2a][1,4]benzodiazepine;







or a pharmaceutically acceptable salt thereof.








15. A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:






















or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition according to claim 2, wherein said farnesyl transferase inhibitor is:








or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition according to claim 16, wherein said farnesyl transferase inhibitor is:



or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition according to claim 17, wherein said anthracyclin is doxorubicin, daunorubicin, epirubicin, idarubicin, or amrubicin, or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition according to claim 17, wherein said anthracyclin is doxorubicin, or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition according to any one of claims 1 - 17, wherein said anthracyclin is doxorubicin, daunorubicin, epirubicin, idarubicin, or amrubicin, or a prodrug thereof, or a pharmaceutically acceptable salt of said anthracyclin or of said anthracyclin prodrug.

21. A pharmaceutical composition according to claim 20, wherein said anthracyclin is doxorubicin, or a pharmaceutically acceptable salt thereof.

22. A method of decreasing the rate of proliferation of nasopharyngeal carcinoma cells, said method comprising contacting said nasopharyngeal cells with a pharmaceutical composition according to claim 18.

23. A method of decreasing the rate of proliferation of nasopharyngeal carcinoma cells, said method comprising contacting said nasopharyngeal cells with a pharmaceutical composition according to claim 19.

24. A method of decreasing the rate of proliferation of nasopharyngeal carcinoma cells, said method comprising contacting said nasopharyngeal cells with a pharmaceutical composition according to claim 20.

25. A method of decreasing the rate of proliferation of nasopharyngeal carcinoma cells, said method comprising contacting said nasopharyngeal cells with a pharmaceutical composition according to claim 21.

26. A method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient a pharmaceutical composition according to claim 18.

27. A method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient a pharmaceutical composition according to claim 19.

28. A method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient a pharmaceutical composition according to claim 20.

29. A method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient a pharmaceutical composition according to claim 21.

30. A method of treating nasopharyngeal carcinoma in a patient, said method comprising administering to said patient an effective amount of one or more farnesyl transferase inhibiting compound in combination with an effective amount of one or more anthracycline compound, wherein said effective amount of said farnesyl transferase inhibiting compound or compounds and of said anthracycline compound or compounds are effective in combination to treat said nasopharyngeal carcinoma.

31. A method according to claim 30 wherein said patient is a mammal.

32. A method according to claim 31 wherein said patient is a human being.

33. A method according to claim 32 wherein said farnesyl transferase inhibiting compound and said anthracycline compound are administered substantially simultaneously.

34. A pharmaceutical kit comprising a composition according to claim 18 and instructions for use of said composition for the treatment of nasopharyngeal carcinoma.

35. A pharmaceutical kit comprising a composition according to claim 19 and instructions for use of said composition for the treatment of nasopharyngeal carcinoma.


36. A pharmaceutical kit comprising a composition according to claim 20 and instructions for use of said composition for the treatment of nasopharyngeal carcinoma.

37. A pharmaceutical kit comprising a composition according to claim 21 and instructions for use of said composition for the treatment of nasopharyngeal carcinoma.

38. A kit comprising: a) a first unit dosage form comprising a farnesyl transferase inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said farnesyl transferase inhibitor or of said farnesyl transferase inhibitor prodrug and a pharmaceutically acceptable carrier, vehicle or diluent; b) a second unit dosage form comprising an anthracycline, a prodrug thereof or a pharmaceutically acceptable salt of said anthracycline or of said anthracycline prodrug and a pharmaceutically acceptable carrier, vehicle or diluent; and c) a container.


39. A kit according to claim 38, wherein said farnesyl transferase inhibitor comprises a compound according to formula I or a pharmaceutically acceptable salt thereof, and said anthracycline comprises doxorubicin, daunorubicin, epirubicin, idarubicin, or amrubicin or a pharmaceutically acceptable salt thereof.

40. A kit according to claim 39, wherein said farnesyl transferase inhibitor comprises a compound according to the formula:



or a pharmaceutically acceptable salt thereof, and said anthracycline comprises doxorubicin or a pharmaceutically acceptable salt thereof.

Figure 1






Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.